cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Halozyme Therapeutics Inc
12 own
10 watching
Current Price
$59.39
$0.13
(0.22%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
5,667.56M
52-Week High
52-Week High
65.53000
52-Week Low
52-Week Low
32.83000
Average Volume
Average Volume
0.7M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
14.5971
iconMarket Capitalization5,667.56M
icon52-Week High65.53000
icon52-Week Low32.83000
iconAverage Volume0.7M
iconDividend Yield--
iconP/E Ratio14.5971
What does the Halozyme Therapeutics Inc do?
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More
How much money does Halozyme Therapeutics Inc make?
News & Events about Halozyme Therapeutics Inc.
Ticker Report
1 year ago
Halozyme Therapeutics, Inc. (NASDAQ:HALO Get Rating) SVP Michael J. Labarre sold 10,000 shares of the companys stock in a transaction dated Wednesday, June 21st. The stock was sold at an average price of $36.00, for a total value of $360,000.00. Following the completion of the ...
PR Newswire
1 year ago
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE PR Newswire SAN DIEGO, March 15, 2023 Company Anticipates No Impact on U.S. and European Royalty Revenues from DARZALEX FASPROand SC through at...
Zolmax
1 year ago
Halozyme Therapeutics (NASDAQ:HALO Get Rating) had its price target decreased by SVB Leerink from $62.00 to $61.00 in a research report released on Wednesday, Benzinga reports. SVB Leerink currently has an outperform rating on the biopharmaceutical companys stock. SVB Leerink also issued estimates ...
PR Newswire
1 year ago
Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO, Jan. 3, 2023 SAN DIEGO, Jan. 3, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ('Halozyme') today...
Zolmax
1 year ago
Halozyme Therapeutics (NASDAQ:HALO Get Rating) had its price target raised by JPMorgan Chase & Co. from $53.00 to $54.00 in a research report sent to investors on Tuesday , Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical companys stock. Several ...
Frequently Asked Questions
Frequently Asked Questions
What is Halozyme Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Halozyme Therapeutics Inc shares?
plus_minus_icon
How can I buy Halozyme Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Halozyme Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Halozyme Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Halozyme Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Halozyme Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Halozyme Therapeutics Inc?
plus_minus_icon
What percentage is Halozyme Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Halozyme Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$59.39
$0.13
(0.22%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Krystal Biotech Inc
Krystal Biotech Inc
$198.79
$13.79 (7.45 %)
NovoCure Limited
NovoCure Limited
$17.23
$0.33 (1.95 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$1.68
$-0.06 (-3.45 %)
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
$31.07
$-2.42 (-7.23 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Krystal Biotech Inc
Krystal Biotech Inc
$198.79
$13.79 (7.45 %)
NovoCure Limited
NovoCure Limited
$17.23
$0.33 (1.95 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$1.68
$-0.06 (-3.45 %)
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
$31.07
$-2.42 (-7.23 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00